Log in

NASDAQ:PRPO - Precipio Stock Price, Forecast & News

-0.05 (-2.92 %)
(As of 02/23/2020 04:00 PM ET)
Today's Range
Now: $1.66
50-Day Range
MA: $1.91
52-Week Range
Now: $1.66
Volume144,399 shs
Average Volume136,559 shs
Market Capitalization$13.31 million
P/E RatioN/A
Dividend YieldN/A
Precipio, Inc, a cancer diagnostics company, provides diagnostic products and services to the oncology market. It also develops a platform to eradicate the problem of misdiagnosis within academic institutions. In addition, the company delivers diagnostic information to physicians and their patients. It has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment, as well as PerkinElmer. Read More…

Industry, Sector and Symbol

Industry Analytical instruments
Current SymbolNASDAQ:PRPO



Sales & Book Value

Annual Sales$2.86 million
Book Value$2.66 per share


Net Income$-15,690,000.00
Net Margins-525.32%


Market Cap$13.31 million
Next Earnings Date4/21/2020 (Estimated)
OptionableNot Optionable

Receive PRPO News and Ratings via Email

Sign-up to receive the latest news and ratings for PRPO and its competitors with MarketBeat's FREE daily newsletter.

Precipio (NASDAQ:PRPO) Frequently Asked Questions

What is Precipio's stock symbol?

Precipio trades on the NASDAQ under the ticker symbol "PRPO."

When did Precipio's stock split? How did Precipio's stock split work?

Shares of Precipio reverse split on Tuesday, June 6th 2017. The 1-30 reverse split was announced on Thursday, May 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2017. An investor that had 100 shares of Precipio stock prior to the reverse split would have 3 shares after the split.

How were Precipio's earnings last quarter?

Precipio (NASDAQ:PRPO) posted its earnings results on Thursday, August, 23rd. The biotechnology company reported ($0.15) EPS for the quarter, missing the consensus estimate of $1.93 by $2.08. The biotechnology company earned $0.82 million during the quarter. Precipio had a negative net margin of 525.32% and a negative return on equity of 94.75%. View Precipio's Earnings History.

When is Precipio's next earnings date?

Precipio is scheduled to release their next quarterly earnings announcement on Tuesday, April 21st 2020. View Earnings Estimates for Precipio.

What price target have analysts set for PRPO?

1 equities research analysts have issued 1-year target prices for Precipio's stock. Their forecasts range from $4.00 to $4.00. On average, they anticipate Precipio's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 141.0% from the stock's current price. View Analyst Price Targets for Precipio.

What is the consensus analysts' recommendation for Precipio?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Precipio in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Precipio.

Has Precipio been receiving favorable news coverage?

News coverage about PRPO stock has trended very negative on Sunday, according to InfoTrie. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Precipio earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the immediate future. View News Stories for Precipio.

Who are some of Precipio's key competitors?

What other stocks do shareholders of Precipio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Precipio investors own include Portola Pharmaceuticals (PTLA), Biocept (BIOC), Inpixon (INPX), Jaguar Health (JAGX), MannKind (MNKD), AEterna Zentaris (AEZS), Cellectar Biosciences (CLRB), Inovio Pharmaceuticals (INO), MEI Pharma (MEIP) and TrovaGene (TROV).

Who are Precipio's key executives?

Precipio's management team includes the folowing people:
  • Mr. Ilan Danieli, Founder, Pres, CEO & Director (Age 47)
  • Mr. Carl R. Iberger, CFO & Sec. (Age 66)
  • Mr. Ahmed Zaki Sabet, Chief Operating Officer (Age 33)
  • Mr. Douglas Sites, VP of Sales
  • Mr. Ayman Mohamed, Sr. VP of R&D and Laboratory Operations (Age 34)

Who are Precipio's major shareholders?

Precipio's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Spark Investment Management LLC (0.42%). Company insiders that own Precipio stock include Ilan Danieli and Randal J Kirk. View Institutional Ownership Trends for Precipio.

Which major investors are selling Precipio stock?

PRPO stock was sold by a variety of institutional investors in the last quarter, including Spark Investment Management LLC. View Insider Buying and Selling for Precipio.

How do I buy shares of Precipio?

Shares of PRPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Precipio's stock price today?

One share of PRPO stock can currently be purchased for approximately $1.66.

How big of a company is Precipio?

Precipio has a market capitalization of $13.31 million and generates $2.86 million in revenue each year. Precipio employs 42 workers across the globe.View Additional Information About Precipio.

What is Precipio's official website?

The official website for Precipio is http://www.precipiodx.com/.

How can I contact Precipio?

Precipio's mailing address is 4 Science Park, New Haven CT, 06511. The biotechnology company can be reached via phone at 203-787-7888 or via email at [email protected]

MarketBeat Community Rating for Precipio (NASDAQ PRPO)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  264 (Vote Outperform)
Underperform Votes:  187 (Vote Underperform)
Total Votes:  451
MarketBeat's community ratings are surveys of what our community members think about Precipio and other stocks. Vote "Outperform" if you believe PRPO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRPO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel